Bortezomib

Bortezomib
Clinical data
Trade namesVelcade, others
Other namesPS-341
AHFS/Drugs.comMonograph
MedlinePlusa607007
License data
Pregnancy
category
  • AU: C
Routes of
administration		Subcutaneous, intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • US: ℞-only
  • EU: Rx-only[2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding83%
MetabolismLiver, CYP extensively involved
Elimination half-life9 to 15 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.125.601 Edit this at Wikidata
Chemical and physical data
FormulaC19H25BN4O4
Molar mass384.24 g·mol−1
3D model (JSmol)
  • O=C(N[C@H](C(=O)N[C@H](B(O)O)CC(C)C)Cc1ccccc1)c2nccnc2
  • InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 checkY
  • Key:GXJABQQUPOEUTA-RDJZCZTQSA-N checkY
  (verify)

Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma.[3] This includes multiple myeloma in those who have and have not previously received treatment.[2] It is generally used together with other medications.[2] It is given by injection.[3]

Common side effects include nausea, diarrhea, tiredness, low platelets, fever, numbness, low white blood cells, shortness of breath, rash and abdominal pain.[3] Other severe side effects include low blood pressure, tumour lysis syndrome, heart failure, and reversible posterior leukoencephalopathy syndrome.[3][2] It is in the class of medications known as proteasome inhibitor.[3] It works by inhibiting proteasomes, cellular complexes that break down proteins.[2]

Bortezomib was approved for medical use in the United States in 2003 and in the European Union in 2004.[3][2] It is on the World Health Organization's List of Essential Medicines.[4] It is available as a generic medication.[5]

  1. ^ "Bortezomib Baxter (Baxter Healthcare Pty Ltd)". Therapeutic Goods Administration (TGA). 2 May 2024. Retrieved 5 October 2024.
  2. ^ a b c d e f "Velcade EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 October 2019.
  3. ^ a b c d e f "Bortezomib Monograph for Professionals". Drugs.com. Retrieved 13 October 2019.
  4. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.